Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial.

摘要: The aim of this study was to evaluate the efficacy cimetropium bromide, a new antimuscarinic compound, in relieving symptoms patients with irritable bowel syndrome over three month period. Seventy consecutive outpatients were given (50 mg tid) or placebo according double blind, randomised, parallel groups design. Symptoms evaluated initially and at monthly intervals up end One patient receiving withdrew because treatment failure. Pain score decreased by 40, 66, 85% group, first, second third months respectively, compared 26, 32 52% reductions among controls (p = 0.0005). At there 86% reduction number abdominal pain episodes per day group 50% 0.001). Constipation diarrhoea scores 59 49% treated patients, 37 39% controls, differences between being not significant. 89% considered themselves as globally improved opposed 69% 0.039). corresponding 95% confidence for proportion two from 11% 29%. Six taking complained slight dry mouth. results showed that bromide is effective syndrome.